Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 367
- Registration Number
- NCT03345914
- Locations
- 🇬🇧
Regeneron Research Site, Sheffield, United Kingdom
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 18
- Registration Number
- NCT03293030
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
Study of REGN3500 and Dupilumab in Patients With Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03112577
- Locations
- 🇺🇸
WCCT Global, Cypress, California, United States
🇬🇧Celerion, Belfast, United Kingdom
🇬🇧Hammersmith Medicine Research, London, United Kingdom
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 251
- Registration Number
- NCT03054428
- Locations
- 🇨🇦
Regeneron Investigational Site, Windsor, Ontario, Canada
🇨🇦Regeneron Research Site, Richmond Hill, Ontario, Canada
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT03050151
- Locations
- 🇺🇸
Regeneron Investigational Site, Tacoma, Washington, United States
Dupilumab Compassionate Use Study
- Conditions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Sally E. Wenzel MD
- Registration Number
- NCT03020810
Evaluation of Dupilumab in Children With Uncontrolled Asthma
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 408
- Registration Number
- NCT02948959
- Locations
- 🇺🇸
Investigational Site Number 840012, Tucson, Arizona, United States
🇺🇸Investigational Site Number 840001, Rolling Hills Estates, California, United States
🇺🇸Investigational Site Number 840016, Ann Arbor, Michigan, United States
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 325
- Registration Number
- NCT02755649
- Locations
- 🇩🇪
Site 7, Berlin, Germany
🇩🇪Site 5, Berlin, Germany
🇬🇧Site 1, London, United Kingdom
Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02647086
- Locations
- 🇺🇸
Regeneron Study Site, Raleigh, North Carolina, United States
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 880
- Registration Number
- NCT02612454
- Locations
- 🇬🇧
Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom
🇩🇪Regeneron Study Site, Muenchen, Germany
🇺🇸Regeneron Investigational site, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.